Cell Medica recently completed two randomized clinical studies to demonstrate the therapeutic benefit of Cytovir CMV for the prevention of infections in bone marrow (hematopoietic stem cell) transplant patients.
A revolutionary approach to treating cancer associated with the oncogenic Epstein Barr virus.
Cytovir ADV, for the treatment of life-threatening adenovirus infections in children, is being tested in a clinical trial with the Institute of Child Health/Great Ormond Street Hospital.
Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer.
Cell Medica’s proprietary production technology enables GMP compliant manufacture of antigen-specific T cells for therapeutic use in infection (Cytovir product group) and cancer (Cytorex ...
Copyright © 2008 - 2014 Cell Medica